

---

N. Friedel, R. Hetzer, D. Royston (Eds.)


# Blood Use in Cardiac Surgery

---



Steinkopff Verlag Darmstadt  
Springer-Verlag New York





042619254  
01.07.1996

The Editors:  
Dr. N. Friedel  
Prof. Dr. R. Hetzer  
Deutsches Herzzentrum Berlin  
Augustenburger Platz 1  
1000 Berlin 65, FRG

Dr. D. Royston  
Harefield Hospital  
Hill End Road  
Harefield  
Middlesex  
UB9 6JH

CIP-Titelaufnahme der Deutschen Bibliothek

**Blood use in cardiac surgery** / N. Friedel . . . (eds.). — Darmstadt  
: Steinkopff; New York: Springer, 1991  
ISBN 3-7985-0841-0 (Steinkopff)  
ISBN 0-387-91372-6 (Springer)  
NE: Friedel, Norbert [Hrsg.]

This work is subject to copyright. Allrights are reserved whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provision of the German Copyright Law of September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.

Copyright © 1991 by Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt  
Medical Editorial: Sabine Müller — English Editor: James C. Willis — Production: Heinz J. Schäfer

Printed in Germany

The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Type-setting, printing and bookbinding: Vereinigte Buchdruckereien, Bad Buchau  
Printed on acid-free paper

# Contents

Foreword .....	V
<b>I. Pathomechanism of Defective Hemostasis During and After Extracorporeal Circulation</b>	
<b>Fibrinolysis</b>	
Bachmann, F., P. Parise .....	3
<b>Pathomechanisms of Defective Hemostasis During and After Extracorporeal Circulation: Contact Phase Activation</b>	
Kluft, C. ....	10
<b>Pathomechanism of Defective Hemostasis During and After Extracorporeal Circulation: The Role of Platelets</b>	
Michelson, A. D. ....	16
<b>Blood-Surface Interaction During Cardiopulmonary Bypass</b>	
Edmunds, L. H. Jr., R. W. Colman, S. Niewiarowski .....	27
<b>A Clinical Study on Platelet Preservation in Coronary Artery Bypass Surgery During Cardiopulmonary Bypass without Oxygenator</b>	
Bochenek, A., Z. Religa, J. Wojnar, A. Wnuk-Wojnar, M. Zembala, J. Hołłowiecki, A. Bochenek .....	37
<b>The Effect of Aprotinin on Platelet Function and Coagulation In Vitro</b>	
Ratnatunga, C. P., P. Gorog, I. B. Kovacs, G. M. Ress .....	41
<b>Clinical Impact of Reduced Blood Cell Deformability During Cardiopulmonary Bypass</b>	
Al-Khaja, N., A. Belboul, B. Liu, D. Roberts .....	44
<b>Diagnostic Value of Hemostatic Parameters for Prediction of Complications in Patients Undergoing Aorto-Coronary Bypass Grafting</b>	
Teufelsbauer, H., M. Havel, P. Knöbl, S. Andert, P. Jaksch, M. Müller, T. Vukovich .....	48
<b>Summary of Lectures, Posters and Discussion: Pathomechanism</b>	
Prentice, C. ....	52
<b>II. Epidemiology — The Size of the Clinical Problem</b>	
<b>Homologous Blood Use in Cardiac Surgery</b>	
Fox, A. ....	59
<b>Blood Use in Cardiac Surgery — A Transfusionist's Viewpoint</b>	
Eckstein, R. ....	63
<b>Current Risks of Blood Transfusion</b>	
Klein, G. ....	69

<b>Blood Use in Adult Cardiac Surgery — Extrapolations from the Carola data base</b>	
Gallandat Huet, R. C. G., A. F. de Geus, H. E. Mungroop, N. Borgstein, T. Keane, J. T. M. Pierce, G. F. Karliczek, A. Eijgelaar . . . . .	74
<b>Evolution of Requirements to Replace Blood and Plasma in Cardiac Surgery</b>	
Marggraf, G., M. Schax, H. Trübenbach, M. Brand, K. R. Flechsenhar, N. Doetsch . . . . .	78
<b>AIDS and Surgery: On the Need to Reduce the Risks of HIV Infection</b>	
Koch, M. G. . . . .	84
<b>Epidemiology — Screening for Infectious Diseases Transmitted Through Blood and Blood Products</b>	
Seidl, S., P. Kühnl . . . . .	101
<b>III: Non-Pharmacological Methods for the Reduction of Blood Use in Cardiac Surgery</b>	
<b>Autologous Blood Predonation</b>	
Kuppe, H., Th. Breitfeld, P. Schmucker . . . . .	111
<b>Resuscitation Fluids for the Treatment of Hemorrhagic Shock in Dogs: The Effects on Myocardial Blood Flow</b>	
Tait, A. R., L. O. Larson . . . . .	119
<b>Reduction of Blood Use in Cardiac Surgery by Topical Hemostasis Using Fibrin Sealant</b>	
Haverich, A. . . . .	124
<b>Retransfusion of Postoperative Drainage Blood</b>	
von der Emde, J., F. O. Mahmoud, H. D. Esperer . . . . .	129
<b>Bacteriological Methods to Monitor the Quality of Intraoperative Autotransfusion</b>	
Ezzedine, H., P. Baele . . . . .	133
<b>Blood Salvage in Cardiac Surgery: Comparative Analysis of Three Procedures</b>	
Walpoth, B., U. Volken, T. Pfäßli, U. Nydegger, U. Althaus . . . . .	139
<b>Inflammatory Response Due to Cell-Saver in Cardiac Surgery</b>	
Loisance, D., A. Liou, Ph. Deleuze, I. Contremoulin, L. Intrator, J. P. Cachera . . . . .	147
<b>Open-Heart Surgery in Jehovahs Witnesses</b>	
Schlosser, V., G. Fraedrich . . . . .	151
<b>Autologous Blood Transfusion in Cardiac Surgery — 15-Year Experience</b>	
Saavedra, C., S. Seidl, P. Satter, M. Kaltenbach, R. Dudziak . . . . .	156

<b>Preoperative Autologous Blood Donation to Minimize Homologous Blood Transfusions</b>	
Sons, H., H. D. Schulte, W. Bircks .....	160
<b>Use of Predonated Autologous Blood in Cardiac Surgery</b>	
Donauer, E., B. Babik, E. Mészáros, G. Gál, G. Kovács .....	164
<b>Blood Use Reduction by Predonation – How Effective is It?</b>	
Achenbach, H., A. Tanzeem, W. Saggau, S. Hagl .....	171
<b>Autologous Blood Transfusion in Cardiac Surgery</b>	
Castro, L., T. Araújo, R. C. Ferreira, J. Q. Melo .....	174
<b>Intraoperative Blood Conservation Using Cell-Saver</b>	
Bhattacharya, S. K., G. P. Sharma, P. I. Polimeni, L. Dyck, M. Roy .....	178
<b>Intraoperative Autotransfusion</b>	
Claeys, L., M. Horsch, G. Hanisch, S. Horsch .....	181
<b>Cardiac Surgery in Jehovah’s Witnesses: An Experience of 62 Cases</b>	
Rigler, B., H. Gombotz, H. Mächler, D. Dacar, Ch. Matzer, K. H. Tscheliessnig, H. Metzler .....	186
<b>Reduction of Homologous Blood Requirement During Myocardial Revascularization – Comparison of Four Different Techniques</b>	
Mitto, H. P., W. Dietrich, A. Barankay, J. A. Richter .....	190

#### **IV. Pharmacological Methods for the Reduction of Blood Use in Cardiac Surgery**

<b>Platelet Dysfunction after Coronary Artery Bypass Surgery</b>	
Teoh, K. H., R. D. Weisel, J. Ivanov, S. J. Teasdale, M. F. X. Glynn .....	195
<b>Clinical Effectiveness of Aprotinin in Heart Surgery</b>	
Royston, D. ....	208
<b>Safety and Risk/Benefit Assessment of Aprotinin in Primary CABG</b>	
Fraedrich, G., K. Neukamm, T. Schneider, M. Haag-Weber, D. Schmidt, C. Weber, V. Schlosser .....	221
<b>Investigation on the Mechanisms of Action of Aprotinin in Cardiac Surgery</b>	
Dietrich, W., M. Spannagl, M. Jochum, P. Wendt, A. Barankay, J. A. Richter .....	232
<b>High-dose Aprotinin Reduces Bleeding in Patients Taking Aspirin at the Time of Aorto-Coronary Bypass Surgery</b>	
Bidstrup, B. P. ....	240
<b>Preserved Hemostasis During the Combined Use of Aprotinin and Aspirin in CABG Operations</b>	
Tabuchi, N., W. van Oeveren, L. Eijnsman, K. J. Roozendaal, Y. J. Gu, Ch. R. H. Wildevuur .....	245

<b>ACT and Aprotinin</b>	
Preiss, D. U., I. Witt, H. Kiefer, P. Betz .....	252
<b>Aprotinin: Effect on “Re-Do” Surgery</b>	
Ross, D. N., J. C. Simpson .....	260
<b>The Edinburgh Experience — Low-dose Trasylol</b>	
Scott, D. H. T., J. Au .....	263
<b>Reduction of Blood Use by Aprotinin After Heart-Transplantation</b>	
Havel, M., H. Teufelsbauer, W. Zwölfer, A. Laczkovics, E. Wolner .....	266
<b>Blood Damage and Activation in Cardiopulmonary Bypass</b>	
Wildevuur, Ch. R. H. ....	269
<b>V. Panel Discussion</b>	
<b>Changing Concepts of Blood Use in Cardiac Surgery</b> .....	277

# Investigation on the Mechanisms of Action of Aprotinin in Cardiac Surgery

W. Dietrich<sup>1</sup>, M. Spannagl<sup>2</sup>, M. Jochum<sup>3</sup>, P. Wendt<sup>4</sup>, A. Barankay<sup>1</sup>, J. A. Richter<sup>5</sup>

<sup>1</sup> Staff Anesthesiologist, Institute for Anesthesiology, German Heart Center, Munich, <sup>2</sup> Research Fellow, Internal Medicine, University Clinic Munich, <sup>3</sup> Research Fellow, Department of Surgery, Division of Clinical Chemistry, University Clinic Munich, <sup>4</sup> Research Fellow, Department of Experimental Surgery, Technical University Munich, <sup>5</sup> Chairman, Institute for Anesthesiology, German Heart Center Munich

## Introduction

Blood loss and bleeding tendency with the consequence of homologous blood transfusion still present a major problem in cardiac surgery. Many efforts have been made to influence the bleeding tendency in open-heart surgery by pharmacological means. Aprotinin is a naturally occurring enzyme inhibitor derived from bovine lungs. It acts on trypsin, plasmin, tissue-kallikrein and, to lesser degree, on plasma-kallikrein [1, 2]. Moreover, it is reported to have direct platelet-preserving properties in very high dosages [3]. Aprotinin has been used in Europe for a long time in varying indications, but only since the results published by Royston et al. [4] who applied very high dosages of aprotinin, has this drug been regarded with increased interest. Recently, these results were corroborated by several studies [5–9].

Based upon previous investigations [7], we postulated that the clinical effect of aprotinin is mainly due to the inhibition of the contact phase of coagulation. During CPB this system is activated by contact of blood with artificial surfaces of the extracorporeal circuit [10]. However, the postoperative bleeding tendency after cardiac surgery seems to be primarily due to impaired platelet function [11]. But the mechanism underlying the benefit from aprotinin has not yet been elucidated completely.

The aim of our present prospective, double-blind, placebo controlled study was to obtain further information about the mode of action of aprotinin.

## Methods

Forty patients scheduled for elective primary myocardial revascularization gave informed consent to participate in this study, which had been approved by the local ethics committee. The study group comprised only male patients with preoperative normal left ventricular function (EF > 40%, LVEDP < 20 mmHg), with a preoperative hemoglobin concentration > 13.5 g/dl, and who were not receiving preoperative anticoagulant treatment or antiplatelet medication.

Patients were randomly assigned to one of two groups: the aprotinin group (group A) and the control (group C). The following dosage regime of aprotinin was applied:

after induction of anesthesia and prior to surgery, patients received a loading dose of  $2 \times 10^6$  KIU aprotinin over a 15-min period, followed by a continuous infusion of  $5 \times 10^5$  KIU per hour administered by an infusion pump during the whole time of surgery. An additional bolus of  $2 \times 10^6$  KIU was added to the pump prime of the heart-lung machine. Patients of group C received an equal volume of saline.

The indication for intra- and postoperative transfusion of homologous blood or blood products was defined in the study protocol as a hematocrit of less than 30 %.

Anesthetic, operative, and bypass management were standardized. Patients were heparinized with 125 units/kg mucosa heparin. Further heparin (125 units/kg) was administered if the activated clotting time (ACT) decreased below 400 s. The extracorporeal circuit consisted of a bubble oxygenator, which was primed with 1400 ml crystalloid solution. After completion of CPB, residual heparin was neutralized with protamine chloride in a ratio of 1.5 mg per 125 units of the initial heparin dosage.

Blood transfusions needed until discharge from the hospital were recorded. Intraoperative blood loss was assessed by weighing the gauzes and sponges and measuring the content of the suction reservoir. Postoperative blood loss was measured as cumulative chest tube output 6, 12, and 24 h postoperatively, as well as at the removal of the chest tubes.

Blood samples were taken at the following times: 1) after induction of anesthesia and prior to aprotinin infusion; 2) prior to heparin administration; 3) 5 min and 4) 30 min after start of CPB; 5) at the end of CPB; 6) after chest closure. After discarding the first 10 ml, blood was drawn into EDTA tubes or into ACC solution (4 : 1).

Tissue plasminogen activator (tPA) concentration, the split products of cross-linked fibrin (D-dimers), total degradation products of fibrinogen and fibrin (FSP), and the complex of thrombin with antithrombin III (TAT) [12] were determined by sandwich ELISA's using polyclonal as well as monoclonal antibodies. Results are given in ng/ml. Aprotinin plasma concentrations were quantified by means of a competitive ELISA, according to Müller-Esterl et al. [13]. Spontaneous fibrinolytic activation in the native samples, as well as in their euglobulin fraction, was estimated on plasminogen containing human fibrin plates [14].

To determine the ACT, the Hemochron 800 (International Technidine Corp., New Jersey, USA) was used. ACT measurements were performed every 30 min and at all intraoperative measurement times.

Summary data of all variables are expressed as means  $\pm$  standard deviation (SD). Analysis of variance (ANOVA) was used if appropriate. Chi-square test was applied for categorical data. A p value less than 0.05 was considered statistically significant.

## Results

Patients' demographic data were comparable in terms of age, weight, operation, and CPB time. Thirteen patients in group C and 11 patients in group A had an additional internal mammary artery implantation.

The assessed intraoperative blood loss was  $636 \pm 322$  ml in group C and  $363 \pm 159$  ml in group A ( $p < 0.05$ ). The mean cumulated loss 6, 12 and 24 h postoperatively was  $721 \pm 471$  ml,  $894 \pm 491$  ml, and  $1169 \pm 605$  ml in group C, and  $303 \pm 209$  ml,  $399 \pm 251$  ml, and  $584 \pm 295$  ml in group A. The total postoperative blood loss until removal of the chest tubes was  $1431 \pm 760$  ml in group



C, and  $738 \pm 411$  ml in group A ( $p < 0.05$ ) (Fig. 1). The mean amount of intra- and postoperatively transfused homologous blood was  $838 \pm 963$  ml/patient in group C and  $163 \pm 308$  ml in group A, respectively ( $p < 0.05$ ).  $2.3 \pm 2.2$  units of homologous blood or blood products were given in group C and  $0.63 \pm 0.96$  units/patient in group A ( $p < 0.05$ ). Twenty-five % of the patients in group C and 63% in group A were discharged from the hospital without receiving any banked blood or homologous blood products. The intraoperative blood loss correlated significantly with CPB time in group C, whereas it did not in group A.

The ACT, which was in a comparable range preoperatively in the two groups, was significantly increased 5 min prior to administration of heparin in group A ( $141 \pm 13$  vs  $122 \pm 25$  s) and remained significantly higher until antagonizing the effect of heparin after CPB. The aPTT was also significantly increased before heparin in group A ( $34 \pm 2.8$  vs  $74 \pm 7.3$  s) ( $p < 0.05$ ) and remained significantly prolonged until 2 h post surgery ( $66 \pm 23$  vs  $45 \pm 25$  s).

The concentration of the TAT complex 30 min after the start of CPB and at the end of CPB showed significant differences ( $p < 0.05$ ) with  $48 \pm 21$  and  $82 \pm 42$  ng/ml (group C) compared to  $24 \pm 11$  and  $42 \pm 14$  ng/ml in group A.

The concentration of the split products of the cross-linked fibrin (D-dimers) increased in both groups during surgery. However, the increase was less in the aprotinin group and was  $532 \pm 1425$  and  $497 \pm 1398$  ng/ml, 30 m in after onset of CPB and at the end of CPB, respectively, significantly less than the values of group C ( $2155 \pm 2300$  and  $3131 \pm 2755$  ng/ml). The FSP concentrations showed a similar course (Fig. 2). At the end of CPB the concentration was  $10\,824 \pm 7261$  ng/ml in group C and  $2510 \pm 3932$  ng/ml in the aprotinin group ( $p < 0.05$ ).

The fibrin plates revealed increased fibrinolytic activity during the entire course of CPB in the control group. In the native samples fibrinolytic activity was evident





Fig. 1. Intra- and postoperative blood loss. The postoperative data are cumulative values.



**Fig. 2.** Total degradation products of fibrinogen and fibrin. Values shown in the graph are mean  $\pm$  SD. There was a significant increase during the whole period of CPB in the control group compared to the aprotinin group.

in 12 patients/5 min and in 13 patients/30 min after onset of CPB in the control group, whereas this could not be demonstrated 5 min after start of CPB, and in 8 patients/30 min after start of CPB in the aprotinin group ( $p < 0.05$ ). The tPA concentration was not significantly different during the course of surgery.

The aprotinin plasma concentration (Fig. 3) demonstrated an increase from  $152 \pm 61$  KIU/ml prior to heparin to  $335 \pm 106$  KIU/ml 5 min after onset of CPB. Thereafter, a continuous decrease was found until the end of CPB ( $191 \pm 62$  KIU/ml).

The postoperative course of all patients was uneventful. There were no clinically relevant side effects that could be attributed to aprotinin treatment.

## Discussion

The present study demonstrates the influence of high-dose aprotinin treatment on intra- and postoperative blood loss. Comparing homogeneous patient groups, a significant reduction of intra- and postoperative blood loss was found in the aprotinin-treated group. This reduction led to a concomitant saving of homologous blood. The postoperative blood loss was reduced by 48%, whereas the banked blood requirement was diminished by nearly 80%.

The differences between the two groups with regard to bleeding and banked blood requirement agree with the results of other authors applying the same or a similar aprotinin dosage regime. The blood-saving effect in these studies varied between 43% [7] and 88% [4] (Table 1). All studies using aprotinin during coronary artery bypass grafting showed nearly identical reductions in blood loss.




Fig. 3. Aprotinin plasma level. The peak value 5 min after the onset of CPB represents the bolus of  $2 \times 10^6$  KIU aprotinin given to the pump prime. Despite the continuous infusion of  $5 \times 10^5$  KIU aprotinin/h the concentration decreased towards the end of CPB and towards the end of operation.

Table 1. Studies on aprotinin in open-heart surgery.

Author	Year	Type of operation	No. of patients	Blood loss	Blood saving
Royston et al. [4]	1987	Redos	22	-80%	88%
v. Oeveren et al. [15]	1987	CABG	22	-47%	-50%
Bidstrup et al. [6]	1989	CABG	80	-46%	-83%
Dietrich et al. [7]	1989	Miscellaneous	152	-29%	-43%
Fraedrich et al. [8]	1989	CABG	80	-46%	-43%
Henze et al. [16]	1989	Miscellaneous	380	-35%	-40%
Dietrich et al. [17]	1989	CABG	40	-48%	-80%
Dietrich et al. [18]	1990	Miscellaneous	1784	-34%	-53%

Nevertheless, the mode of action of aprotinin is not yet completely clear. Capillary bleeding and oozing in cardiac surgery are supposed to be due to impaired platelet function [11, 19]. The most important consequence of CPB is the loss of platelet aggregability [10]. The influence of aprotinin on platelet adhesive receptors could be demonstrated in one study [9]. Consequently, a direct platelet-preserving property of aprotinin has been postulated [9, 15].

The surface-mediated activation of the contact system of coagulation involves the interaction of Factor XII (Hageman factor) and kallikrein (besides high molecular weight kininogen and Factor XI) [20]. Aprotinin may inhibit kallikrein. Without the amplifying effect of kallikrein on the conversion of Factor XII to XIIa the contact phase activation is inhibited or takes place only slowly. Major consequences of the surface-mediated activation are the stimulation of both the intrinsic pathway of coagulation [21] with the effect of thrombin formation and the propagation of the fibrinolytic pathway leading to plasminogen activation. Thrombin is a powerful

platelet activator. Therefore, it is conceivable that the effect of aprotinin on platelets is secondary to the inhibition of the contact system of coagulation (Fig. 4)

Aprotinin is a strong plasmin inhibitor [22]. While we observed differences in the results of the fibrin plates between the groups, we could not detect any significant difference in the course of tPA concentration. The current findings indicate, that endothelial activation of fibrinolysis is not inhibited by aprotinin, whereas the activation via plasma kallikrein is attenuated. The course of the ACT, which is an indicator of contact activation [23], as well as the aPTT elevation with aprotinin treatment refer to the inhibition of the contact phase of coagulation. These hemostasiological results strongly suggest, that the inhibition of the contact phase of coagulation is the primary effect of aprotinin and is thus responsible for its blood-saving effect. This finding is in contrast to the interpretation given by van Oeveren et al. [9, 15], who focused on the direct platelet protective effect of aprotinin on the specific platelet receptors.

The rationale for choosing the given aprotinin dose regime was to get a constant aprotinin plasma level of more than 200 KIU/ml, which is supposed to be the threshold of plasma kallikrein inhibition [24]. The course of plasma aprotinin level revealed that aprotinin dosage was not able to maintain a stable concentration throughout CPB. However, the concentration exceeded 200 KIU/ml after onset of CPB. The course of the fibrin-fibrinogen split products and the results of the fibrin plates demonstrated that aprotinin was not able to suppress the ongoing hemostatic activation totally. All parameters showed an increase towards the end of CPB. Further investigation is needed to ascertain whether this tendency can be prevented with an even higher dose regime of aprotinin during CPB.




Fig. 4. Aprotinin action on the hemostatic system.

The results of this study suggest that the most likely mechanism of action of aprotinin is the inhibition of the contact phase of coagulation. This is due to the ability of aprotinin to inhibit kallikrein. It acts supplementary to heparin on coagulation. The combination of both drugs provides an enhanced anticoagulatory effect. However, because aprotinin only acts on the contact phase of coagulation, it is not recommended to reduce the heparin dosage under aprotinin. The better preserved platelet function and the inhibition of fibrinolysis is secondary to the better preserved coagulation system.

In conclusion, high-dose aprotinin treatment has a highly beneficial effect on the hemostatic mechanism during and after CPB, leading to a substantial reduction of intra- and postoperative bleeding tendency. The most likely mechanism of aprotinin action is the inhibition of kallikrein and not a direct platelet-preserving property.

## References

1. Emerson FE (1989) Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. *Cardiovasc Drug Rev* 7: 127–140
2. Fritz H (1985) The target enzymes of aprotinin in vitro and in vivo. *Proteolyse und Proteinaseinhibition in der Herz- und Gefäßchirurgie*, 143–154
3. Aoki N, Naito K, Yoshida N (1978) Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. *Blood* 52: 1–12
4. Royston D, Taylor KM, Bidstrup BP, Sapsford RN (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. *Lancet*, ii: 1289–1291
5. Alajmo F, Calamai G, Perna AM et al (1989) High-Dose Aprotinin: Hemostatic effects in open-heart operations. *Ann Thorac Surg* 48: 536–539
6. Bidstrup BP, Royston D, Sapsford RN, Taylor KM (1989) Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). *J Thorac Cardiovasc Surg* 97: 364–372
7. Dietrich W, Barankay A, Dilthey G, et al (1989) Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application — clinical experience in 152 cardiac surgical patients. *Thorac Cardiovasc Surgeon* 37: 92–98
8. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V (1989) Reduction of blood transfusion requirement in open-heart surgery by administration of high doses of aprotinin — preliminary results. *Thorac Cardiovasc Surgeon* 37: 89–91
9. van Oeveren W, Harder MP, Roozendaal KJ, Eijnsman L, Wildevuur CRH (1990) Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 99: 788–797
10. Edmunds LH, Ellison N, Colman WR, et al (1982) Platelet function during cardiac operation — comparison of membran and bubble oxygenators. *J Thorac Cardiovasc Surg* 83: 805–812
11. Harker LA (1986) Bleeding after cardiopulmonary bypass. *N Engl J Med* 314: 446–448
12. Bauer KA, Rosenberger RD (1984) Thrombin generation in acute promyelocytic leukemia. *Blood* 64: 64
13. Müller-Esterl W, Oetl A, Trucheit E, Fritz H (1984) Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA). *Fresenius Z Anal Chem* 317: 718
14. Wendt P, Fritsch A, Schulz F, Wunderlich G, Blümel G (1984) Proteinases and inhibitors in plasma and peritoneal exudate in acute pankreatitis. *Hepato-gastroenterol* 31: 277–281
15. van Oeveren W, Jansen NJG, Bidstrup BP, et al (1987) Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. *Ann Thorac Surg* 44: 640–645
16. Henze R, Dietrich W, Hähnel C, Sebening F, Richter JA (1989) Verminderter Blutverbrauch in der Herzchirurgie durch intraoperative Aprotininapplikation. *Anästhesist* 38: 510
17. Dietrich W, Spannagl M, Jochum M, Wendt P, Sebening F, Richter JA (1989) Reduction of homologous blood requirement in cardiac surgery using high-dose aprotinin. *Anesthesiology (Suppl)*

18. Dietrich W, Hähnel C, Richter JA (1990) Routine application of high-dose aprotinin in open-heart surgery — a study on 1784 patients. *Anesthesiology (Suppl)*, in press
19. Edmunds LH (1989) Letter to the editor: Blood platelets and bypass. *J Thorac Cardiovasc Surg* 97: 470—477
20. Colman RW (1984) Surface-mediated defense reactions. The plasma contact activation system. *J Clin Invest* 73: 1249—1253
21. Carvalho AC, De Marinis S, Scott CF, Silver LD, Schmaier AH, Colman RW (1988) Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. *J Lab Clin Med* 112: 270—277
22. Verstraete M (1985) Clinical application of inhibitors of fibrinolysis. *Drugs* 29: 236—261
23. Hattersley PG (1966) Activated coagulation time of whole blood. *JAMA* 196: 436—440
24. Fritz H, Wunderer G. (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. *Arzneim Forsch/Drug Res* 33: 479—494

Authors' address:

W. Dietrich, M.D.

Institute for Anesthesiology

German Heart Center Munich

Lothstraße 11

8000 Munich 2, FRG